{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:09:24Z","timestamp":1788566964914,"version":"build-2803163510"},"reference-count":62,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombotic microangiopathy (TMA) encompasses various genetically-driven diseases. The emergence of ultrafast genomic sequencing has recently opened up new avenues of research for genetic investigations in the setting of intensive care units. TMA is likely to be a suitable focus for fast-track genomic sequencing. By establishing an expeditious molecular diagnosis of patients with the complement-dependent hemolytic uremic syndrome, fast-track genomic sequencing allows for the timely implementation or withdrawal of anti-C5 treatment while averting unnecessary, costly, and potentially harmful therapy in patients testing negative for the syndrome. Furthermore, genomics has the potential to reshape the taxonomic classification of TMA owing to comprehensive genomic analysis. The most significant results from such analysis can be categorized as (1) new descriptions of genetic diseases previously not recognized as associated with TMA and (2) an enrichment of the phenotypic spectrum of diseases traditionally related to TMA. The latter draws on the concept of retrophenotyping, wherein genomic investigation precedes full clinical description. By taking precedence over a phenotypic approach, an unbiased genomic-focused analysis maximizes the chances of discovering new descriptions of a given variant. Presented here are 4 cases of TMA which highlight these issues and substantiate the promise of fast-track genomic sequencing.<\/jats:p>","DOI":"10.1182\/blood.2022015583","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T17:05:56Z","timestamp":1667927156000},"page":"147-155","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["How I treat thrombotic microangiopathy in the era of\u00a0rapid genomics"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5145-5000","authenticated-orcid":false,"given":"Alice","family":"Doreille","sequence":"first","affiliation":[{"name":"1Service de Soins Intensifs N\u00e9phrologique et Rein Aigu, H\u00f4pital Tenon, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"2Facult\u00e9 de M\u00e9decine, Sorbonne Universit\u00e9, Paris, France"},{"name":"3France Intensive Renal Network"},{"name":"4Centre national de R\u00e9f\u00e9rence Microangiopathie Thrombotique (CNR MAT), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1093-0514","authenticated-orcid":false,"given":"C\u00e9dric","family":"Rafat","sequence":"additional","affiliation":[{"name":"1Service de Soins Intensifs N\u00e9phrologique et Rein Aigu, H\u00f4pital Tenon, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"3France Intensive Renal Network"},{"name":"4Centre national de R\u00e9f\u00e9rence Microangiopathie Thrombotique (CNR MAT), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rondeau","sequence":"additional","affiliation":[{"name":"1Service de Soins Intensifs N\u00e9phrologique et Rein Aigu, H\u00f4pital Tenon, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"2Facult\u00e9 de M\u00e9decine, Sorbonne Universit\u00e9, Paris, France"},{"name":"3France Intensive Renal Network"},{"name":"4Centre national de R\u00e9f\u00e9rence Microangiopathie Thrombotique (CNR MAT), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-3757","authenticated-orcid":false,"given":"Laurent","family":"Mesnard","sequence":"additional","affiliation":[{"name":"1Service de Soins Intensifs N\u00e9phrologique et Rein Aigu, H\u00f4pital Tenon, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"2Facult\u00e9 de M\u00e9decine, Sorbonne Universit\u00e9, Paris, France"},{"name":"3France Intensive Renal Network"},{"name":"4Centre national de R\u00e9f\u00e9rence Microangiopathie Thrombotique (CNR MAT), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023082419143477600_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41436-020-00963-4","article-title":"Clinical impact of genomic testing in patients with suspected monogenic kidney disease","volume":"23","author":"Jayasinghe","year":"2021","journal-title":"Genet Med"},{"issue":"5","key":"2023082419143477600_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s40620-020-00898-8","article-title":"Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience","volume":"34","author":"Vaisitti","year":"2021","journal-title":"J Nephrol"},{"issue":"2","key":"2023082419143477600_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2023082419143477600_bib4","first-page":"2079","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Doreille","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023082419143477600_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ndt\/gfaa363","article-title":"Genetics-first approach improves diagnostics of ESKD patients &lt;50 years","volume":"37","author":"Snoek","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2023082419143477600_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.13581021","article-title":"How I treat complement-mediated TMA","volume":"17","author":"Sperati","year":"2022","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"8","key":"2023082419143477600_bib7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00431-019-03399-4","article-title":"RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit-successes and challenges","volume":"178","author":"Elliott","year":"2019","journal-title":"Eur J Pediatr"},{"issue":"5","key":"2023082419143477600_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ajhg.2020.10.004","article-title":"A\u00a0prospective study of parental perceptions of rapid whole-genome and -exome sequencing among seriously ill infants","volume":"107","author":"Cakici","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"24","key":"2023082419143477600_bib9","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2020.7671","article-title":"Feasibility of ultra-rapid exome sequencing in critically ill infants and children with suspected monogenic conditions in the Australian public health care system","volume":"323","author":"Lunke","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2023082419143477600_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41525-020-00168-3","article-title":"Learning from scaling up ultra-rapid genomic testing for critically ill children to a national level","volume":"6","author":"Best","year":"2021","journal-title":"NPJ Genomic Med"},{"issue":"22","key":"2023082419143477600_bib11","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMc2100365","article-title":"Rapid sequencing-based diagnosis of thiamine metabolism dysfunction syndrome","volume":"384","author":"Owen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023082419143477600_bib12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2215\/CJN.11830720","article-title":"Inherited kidney complement diseases","volume":"16","author":"Lemaire","year":"2021","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"4","key":"2023082419143477600_bib13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.2015101189","article-title":"Thrombotic microangiopathy in inverted formin 2-mediated renal disease","volume":"28","author":"Challis","year":"2017","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"9997","key":"2023082419143477600_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(15)00076-8","article-title":"Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency","volume":"386","author":"Grang\u00e9","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"2023082419143477600_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2215\/CJN.11890720","article-title":"Nephronophthisis in young adults phenocopying thrombotic microangiopathy and severe nephrosclerosis","volume":"16","author":"Doreille","year":"2021","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"2023082419143477600_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41467-017-02306-5","article-title":"A\u00a0PRDX1 mutant allele causes a MMACHC secondary epimutation in cblC patients","volume":"9","author":"Gu\u00e9ant","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"2023082419143477600_bib17","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/ajmg.a.40532","article-title":"A\u00a0novel autosomal dominant mutation in SOX18 resulting in a fatal case of hypotrichosis-lymphedema-telangiectasia syndrome","volume":"176","author":"Wangberg","year":"2018","journal-title":"Am J Med Genet A"},{"issue":"6","key":"2023082419143477600_bib18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/375614","article-title":"Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia","volume":"72","author":"Irrthum","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2023082419143477600_bib19","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2007-07-100412","article-title":"Sox18 and Sox7 play redundant roles in vascular development","volume":"111","author":"Cermenati","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2023082419143477600_bib20","doi-asserted-by":"crossref","first-page":"135.e1","DOI":"10.1016\/j.cjca.2015.04.004","article-title":"Aortic dilatation associated with a de novo mutation in the SOX18 gene: expanding the clinical spectrum of hypotrichosis-lymphedema-telangiectasia syndrome","volume":"32","author":"W\u00fcnnemann","year":"2016","journal-title":"Can J Cardiol"},{"issue":"24","key":"2023082419143477600_bib21","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2023082419143477600_bib22","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2023082419143477600_bib23","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419143477600_bib24","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood-2019-129375","article-title":"Plasma exchange in thrombotic microangiopathy: is it time sensitive?","volume":"134","author":"Malapati","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2023082419143477600_bib25","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2023082419143477600_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023082419143477600_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2023082419143477600_bib28","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023082419143477600_bib29","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2023082419143477600_bib30","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2023082419143477600_bib31","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic uremic syndrome: a prospective multicentric study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023082419143477600_bib32","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2023082419143477600_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"2023082419143477600_bib34","first-page":"422","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertens Dallas Tex 1979"},{"issue":"12","key":"2023082419143477600_bib35","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"4","key":"2023082419143477600_bib36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023082419143477600_bib37","unstructured":"Carter J . Does kidney histology predict renal response or complement status in atypical hemolytic uremic syndrome? Paper presented at: American Society of Nephrology Congress; 22 October 2020; virtual meeting.. Accessed March 2021. https:\/\/www.asn-online.org\/education\/kidneyweek\/2020\/program-abstract.aspx?controlId=3438803."},{"issue":"12","key":"2023082419143477600_bib38","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"1","key":"2023082419143477600_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex\u00a0vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023082419143477600_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13023-022-02179-y","article-title":"Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists","volume":"17","author":"Kalantari","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2023082419143477600_bib41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2023082419143477600_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jmd2.12179","article-title":"Outcomes of patients with cobalamin C deficiency: a single center experience","volume":"57","author":"Bourque","year":"2021","journal-title":"JIMD Rep"},{"issue":"9997","key":"2023082419143477600_bib43","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00077-X","article-title":"Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?","volume":"386","author":"George","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"2023082419143477600_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10545-010-9161-z","article-title":"Cobalamin C defect: natural history, pathophysiology, and treatment","volume":"34","author":"Martinelli","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"2023082419143477600_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-016-9991-4","article-title":"Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency","volume":"40","author":"Huemer","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"2023082419143477600_bib46","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","article-title":"Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity","volume":"32","author":"Beck","year":"2017","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"5","key":"2023082419143477600_bib47","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ekir.2018.05.015","article-title":"Cobalamin C deficiency induces a typical histopathological pattern of renal arteriolar and glomerular thrombotic microangiopathy","volume":"3","author":"Lemoine","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2023082419143477600_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.ajkd.2020.07.003","article-title":"Phenocopies, phenotypic expansion, and coincidental diagnoses: time to abandon targeted gene panels?","volume":"76","author":"Ahram","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2023082419143477600_bib49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.ajkd.2019.12.008","article-title":"Exome sequencing and identification of phenocopies in patients with clinically presumed hereditary nephropathies","volume":"76","author":"Riedhammer","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"2023082419143477600_bib50","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijerph17228363","article-title":"Look alike, sound alike: phenocopies in steroid-resistant nephrotic syndrome","volume":"17","author":"Becherucci","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"7492","key":"2023082419143477600_bib51","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/507294a","article-title":"Technology: the $1,000 genome","volume":"507","author":"Hayden","year":"2014","journal-title":"Nature"},{"key":"2023082419143477600_bib52","unstructured":"National Human Genome Research Institute . The Cost of Sequencing a Human Genome. 2021. Accessed 4 March 2021. https:\/\/www.genome.gov\/about-genomics\/fact-sheets\/Sequencing-Human-Genome-cost."},{"key":"2023082419143477600_bib53","unstructured":"Imaging Technology News . MRI costs. Published 30 October 2018. Accessed 30 September 2021. https:\/\/www.itnonline.com\/content\/mri-costs."},{"key":"2023082419143477600_bib54","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Soliris (eculizumab) - avis \u00e9conomique. Published online 13 October 2020. Accessed March 2021. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-12\/soliris_13102020_avis_economique.pdf."},{"key":"2023082419143477600_bib55","unstructured":"Pollack Andrew . Alexion to Buy Synageva BioPharma in $8.4 Billion Deal. The New York Times. 2016. Accessed 14 December 2021. https:\/\/www.nytimes.com\/2015\/05\/07\/business\/dealbook\/alexion-to-buy-synageva-biopharma-in-8-4-billion-deal.html."},{"issue":"5","key":"2023082419143477600_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"2023082419143477600_bib57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"2","key":"2023082419143477600_bib58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2011-03-339903","article-title":"A\u00a0novel hybrid CFH\/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome","volume":"119","author":"Francis","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2023082419143477600_bib59","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1371\/journal.pmed.0030431","article-title":"Atypical haemolytic uraemic syndrome associated with a hybrid complement gene","volume":"3","author":"Venables","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"2023082419143477600_bib60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs)","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"key":"2023082419143477600_bib61","volume-title":"GeneReviews","author":"Noris","year":"1993"},{"issue":"2","key":"2023082419143477600_bib62","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2021.05.008","article-title":"Establishing a nephrology genetic clinic","volume":"100","author":"Pinto e Vairo","year":"2021","journal-title":"Kidney Int"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/2\/147\/2073221\/blood_bld-2022-015583-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/2\/147\/2073221\/blood_bld-2022-015583-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T08:03:08Z","timestamp":1701331388000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/2\/147\/487048\/How-I-treat-thrombotic-microangiopathy-in-the-era"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015583","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}